EUVIMEDEUVIMED entdecken
Crossref

The cyclin‐dependent kinase inhibitor AT7519 is a human RORγt agonist

Kaja Karaś, Joanna Pastwińska, Anna Sałkowska, Iwona Karwaciak, Rafał A Bachorz, Marcin Ratajewski

Immunology & Cell Biology · 2025

DOI: 10.1111/imcb.12851 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology & Cell Biology, 2025. Verfasst von Kaja Karaś und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Epigenetics, Institute of Medical Biology, Polish Academy of Sciences, Łódź, Poland. Hauptthemen laut MEDLINE: Nuclear Receptor Subfamily 1, Group F, Member 3, Cyclin-Dependent Kinases, Protein Kinase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AT7519, which inhibits multiple cyclin‐dependent kinases, has been extensively investigated in various types of cancer cells. Previous studies have demonstrated the ability of this molecule to suppress the expression of the nuclear receptor retinoic acid–related orphan receptor gamma (RORγ) and several genes involved in hepatocellular carcinoma progression. In this study, we identified a distinct agonistic effect of AT7519 on RORγt, an isoform expressed by various immune cells, including T helper 17 lymphocytes. These immune cells play pivotal roles in shaping the tumor microenvironment and promoting the anticancer response of the immune system. After exposure to AT7519 during differentiation, primary human CD4 + T cells presented increased expression of IL17A/F , IFNG and GZMB and decreased expression of PDCD1 and CTLA4 . These findings elucidate a previously unrecognized facet of AT7519 activity and suggest the potential incorporation of this molecule into immune therapies to augment the effectiveness of diverse anticancer strategies involving anti–programmed cell death protein 1 (anti–PD‐1) and anti–cytotoxic T‐lymphocyte antigen 4 (anti– CTLA4 ) regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nuclear Receptor Subfamily 1, Group F, Member 3Cyclin-Dependent KinasesProtein Kinase InhibitorsHumansProgrammed Cell Death 1 ReceptorCTLA-4 AntigenInterferon-gammaCell DifferentiationCD4-Positive T-LymphocytesInterleukin-17Th17 Cells

Stichwörter der Autor:innen

AT7519IL17RORγthepatocellular carcinoma

Substanzen

Nuclear Receptor Subfamily 1, Group F, Member 3Programmed Cell Death 1 ReceptorCyclin-Dependent KinasesCTLA-4 AntigenInterferon-gammaProtein Kinase InhibitorsInterleukin-17PDCD1 protein, human

Autor:innen und Institutionen

  • Laboratory of Epigenetics, Institute of Medical Biology, Polish Academy of Sciences, Łódź, Poland.
  • Laboratory of Molecular Modeling, Institute of Medical Biology, Polish Academy of Sciences, Łódź, Poland.

Förderung

  • Narodowe Centrum Nauki

Zitieren

APA

Karaś, K., Pastwińska, J., Sałkowska, A., Karwaciak, I., Bachorz, R. A., & Ratajewski, M. (2025). The cyclin‐dependent kinase inhibitor AT7519 is a human RORγt agonist. Immunology & Cell Biology. https://doi.org/10.1111/imcb.12851

Vancouver

Karaś K, Pastwińska J, Sałkowska A, Karwaciak I, Bachorz RA, Ratajewski M. The cyclin‐dependent kinase inhibitor AT7519 is a human RORγt agonist. Immunology & Cell Biology. 2025. doi:10.1111/imcb.12851

BibTeX
@article{Kara2025,
  author = {Karaś, Kaja and Pastwińska, Joanna and Sałkowska, Anna and Karwaciak, Iwona and Bachorz, Rafał A and Ratajewski, Marcin},
  title = {The cyclin‐dependent kinase inhibitor AT7519 is a human RORγt agonist},
  journal = {Immunology & Cell Biology},
  year = {2025},
  doi = {10.1111/imcb.12851}
}
Kostenlos starten →